Navigation Links
Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Date:10/16/2009

EAST HANOVER, N.J., Oct. 16 /PRNewswire/ -- The Alabama Supreme Court today overturned a jury verdict against Novartis Pharmaceuticals Corporation (NPC), and directed entry of judgment in favor of NPC. NPC is pleased that the Alabama Supreme Court has found in our favor, which demonstrates that the State of Alabama's claims were unfounded. The State of Alabama had claimed that the prices provided by NPC to reporting services resulted in overpayment to pharmacists and doctors in the Alabama State Medicaid system, and a Montgomery County Circuit Court jury initially found NPC liable.

NPC was among 73 pharmaceutical manufacturers named in a lawsuit filed in 2005 by the Alabama Attorney General. Through the appeal process, NPC demonstrated that it reported true and accurate prices, based on terms that have been known and used by all participants in pharmaceuticals markets, including Alabama Medicaid, for more than 30 years.

"We're pleased by the Alabama Supreme Court's ruling today," said Ludwig Hantson, PhD, Head of Pharma North America, CEO, Novartis Pharmaceuticals Corporation. "NPC is committed to high ethical standards in the pricing, marketing and sale of all of our products."

NPC's mission is to help patients and provide access to medications that treat disease, ease suffering and improve people's lives. In 2008 alone, NPC provided approximately $4.1M in prescription drugs to over 2,100 low-income Alabamans through our Patient Assistance Program.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by express or implied discussions regarding the potential outcome of any other pricing litigation. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nk3569/future_horizons ... "Future Horizons and Growth Strategies in the European ... Forecasts" report to their offering. ... Blood Banking Market 2015 is a new five-countrystrategic ... and potential market entrants identify and evaluate emerging ...
(Date:7/1/2015)... , July 1, 2015 Rock Creek Pharmaceuticals, ... focused on chronic inflammatory disease and neurologic disorders, announced ... study with anatabine citrate, the Company,s lead compound. Results ... of anatabine citrate can significantly inhibit the activation of ... Company is developing this compound in a Phase 1 ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
Breaking Medicine Technology:European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3
... 12 CVS Caremark Corporation (NYSE: CVS ) today announced ... of approximately 15%, to 8.75 cents per share on the Common ... record on January 22, 2010 . This increase translates into an annual ... per share from the previous rate of 30.5 cents . , ...
... , ST. JOSEPH, Mich. , Jan. 12 ... announced today they have been awarded a $336K Phase I ... for creating a novel type of predictive signatures for drug ... should overcome many shortcomings of existing methods of molecular diagnostics. ...
Cached Medicine Technology:CVS Caremark Corporation Increases Quarterly Dividend 15% 2GeneGo Receives SBIR Grant 2GeneGo Receives SBIR Grant 3
(Date:7/1/2015)... ... July 01, 2015 , ... Did you know that infertility in men is ... we at Advanced Fertility Center of Texas (AFCT) would like to talk about some ... is often considered to be a “woman’s issue,” male fertility factors can play a ...
(Date:7/1/2015)... TX (PRWEB) , ... July 01, 2015 , ... As ... another symptom found in a significant number of women: leg pain. Northeast Houston Vein ... , Leg pain, a symptom of venous reflux disease, is underdiagnosed and often overlooked. ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Trevor L. Williams, ... South Florida and continued at USF earning a Master’s degree in Microbiology. He graduated ... member of the American Dental Association, the Florida Dental Association and the Academy of ...
(Date:7/1/2015)... ... 01, 2015 , ... Element Blue ™, a leading ... it has received trademark protection for its SensorInsight® computer software platform. SensorInsight® is ... multiple sources providing an environment where users can view and compare real-time and ...
(Date:7/1/2015)... ... July 01, 2015 , ... A Priority Setting ... a top ten list they hope will guide future mesothelioma research. Surviving Mesothelioma ... it now. , More than 450 mesothelioma patients, caregivers, and healthcare ...
Breaking Medicine News(10 mins):Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2
... ... ... , , ... HARRISBURG, Pa. , ...
... ... ... ... ...
... alliance the Multilateral Initiative on Malaria (MIM), which advocates ... research environments in Africa. Malaria research has historically been ... has led to a huge gap in knowledge in ... in those areas where people are most affected by ...
... ... for the Apple iPhone and iTouch. The innovative torque application is the first of its ... San Diego, CA (PRWEB) February ... for the Apple iPhone and iTouch. The innovative torque application is the first of its ...
... ... has designated Houston Northwest Medical Center as a Blue Distinction Center for Spine Surgery. ... Houston, TX (Vocus) February 22, ... as a Blue Distinction Center for Spine Surgery. Blue Distinction Centers for Spine Surgery are ...
... ... ... ... ...
Cached Medicine News:Health News:Statewide Poll: Pennsylvania Must Adequately Fund Senior Care Services 2Health News:Statewide Poll: Pennsylvania Must Adequately Fund Senior Care Services 3Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 2Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 3Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 4Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 5Health News:Malaria research must be based in Africa 2Health News:Flexible Assembly Systems Announces New Torque Calculator App for the iPhone 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 3Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 4Health News:AppDynamics Announces General Availability of AppDynamics v2.0 2Health News:AppDynamics Announces General Availability of AppDynamics v2.0 3Health News:AppDynamics Announces General Availability of AppDynamics v2.0 4Health News:AppDynamics Announces General Availability of AppDynamics v2.0 5Health News:AppDynamics Announces General Availability of AppDynamics v2.0 6Health News:AppDynamics Announces General Availability of AppDynamics v2.0 7Health News:AppDynamics Announces General Availability of AppDynamics v2.0 8Health News:AppDynamics Announces General Availability of AppDynamics v2.0 9
2.5 mm x 0.6 mm. Overall length: 122 mm, 4.8 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: